No Data
No Data
JPMorgan to Wager on Weight-Loss Craze With $500 Million Fund
JPMorgan Chase & Co.’s asset-management arm raised more than $500 million for a biotech venture-capital fund that will bet on the hottest corner of health care: weight-loss drugs
GLP-1 Obesity Drug Coverage Dropped by Blue Cross Michigan: Report
Express News | Altimmune Presents Data at Easl International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (Mash)
Altimmune Presents Data at EASL International Liver Congress(TM) 2024 Supporting the Disease...
How Is The Market Feeling About Altimmune?
Altimmune's (NYSE:ALT) short percent of float has risen 3.37% since its last report. The company recently reported that it has 23.06 million shares sold short, which is 32.78% of all regular shares th
SA Asks: Which Weight-loss Stocks Should Investors Be Watching?
No Data